Mohammed Abukhattab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammed Abukhattab has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Muna Al Maslamani
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
6 shared publications - Abdullatif Al-Khal
Hamad Medical Corporation, Doha, Qatar
5 shared publications - Ahmed Zaqout
Communicable Diseases Centre Hamad Medical Corporation Doha Qatar
5 shared publications - Ali Senosi Omrani
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
5 shared publications - Fahmi Yousef Khan
Department of Medicine, Hamad General Hospital, Doha, Qatar
5 shared publications - Joanne Daghfal
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
5 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (5) , 1425-1449
Respiratory Syncytial Virus Immunization Strategies for Older Adults in Gulf Cooperation Council Countries: Expert Consensus and Recommendations
Respiratory syncytial virus (RSV) poses a significant health risk to older adults, particularly those with chronic comorbidities, in the Gulf Cooperation Council (GCC) countries. Despite its high burden, RSV remains underrecognized among older adults in this region. This manuscript aims to highlight the burden of RSV among older adults in GCC countries and provide expert consensus recommendations for the implementation of targeted prevention measures, including vaccination strategies. A multidisciplinary panel of experts from GCC countries reviewed international, regional, and country-level data on RSV. The panel formulated recommendations on the basis of a comprehensive literature review and expert consensus, focusing on the integration of RSV vaccination into routine immunization programs for older adults. Older adults, especially those with chronic conditions including but not limited to cardiovascular disease, chronic kidney disease, chronic lung disease, and diabetes, are at an increased risk for severe RSV-related outcomes. Effective vaccines present an opportunity to significantly reduce the incidence and severity of RSV in this vulnerable population. Key recommendations for safeguarding older adults in GCC countries include implementing clear immunization schedules for adults at a country-level that include targeted RSV vaccination, especially among high-risk groups. Providing continuous education for healthcare professionals, increasing vaccine availability, equity, and affordability, conducting public awareness campaigns, and strengthening local surveillance systems also play a crucial role in addressing vaccine-preventable diseases such as RSV. Integrating RSV vaccination into routine immunization schedules, alongside other key vaccines, is essential for achieving comprehensive and optimal protection for older adults in GCC countries.
- 30 March 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (5) , 1425-1449
Open AccessRespiratory Syncytial Virus Immunization Strategies for Older Adults in Gulf Cooperation Council Countries: Expert Consensus and Recommendations
Respiratory syncytial virus (RSV) poses a significant health risk to older adults, particularly those with chronic comorbidities, in the Gulf Cooperation Council (GCC) countries. Despite its high burden, RSV remains underrecognized among older adults in this region. This manuscript aims to highlight the burden of RSV among older adults in GCC countries and provide expert consensus recommendations for the implementation of targeted prevention measures, including vaccination strategies. A multidisciplinary panel of experts from GCC countries reviewed international, regional, and country-level data on RSV. The panel formulated recommendations on the basis of a comprehensive literature review and expert consensus, focusing on the integration of RSV vaccination into routine immunization programs for older adults. Older adults, especially those with chronic conditions including but not limited to cardiovascular disease, chronic kidney disease, chronic lung disease, and diabetes, are at an increased risk for severe RSV-related outcomes. Effective vaccines present an opportunity to significantly reduce the incidence and severity of RSV in this vulnerable population. Key recommendations for safeguarding older adults in GCC countries include implementing clear immunization schedules for adults at a country-level that include targeted RSV vaccination, especially among high-risk groups. Providing continuous education for healthcare professionals, increasing vaccine availability, equity, and affordability, conducting public awareness campaigns, and strengthening local surveillance systems also play a crucial role in addressing vaccine-preventable diseases such as RSV. Integrating RSV vaccination into routine immunization schedules, alongside other key vaccines, is essential for achieving comprehensive and optimal protection for older adults in GCC countries.
- Open Access
- 1 January 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2026 (4)
Epidemiological, clinical characteristics and outcomes of RSV infection in adult patients in Qatar
Background: Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of respiratory illness in adults, particularly among older individuals and those with chronic comorbidities. Data on RSV epidemiology and outcomes in the Middle East remain limited, which is particularly important given the high burden of chronic metabolic diseases in the region and its potential implications. Objective: To evaluate the epidemiology, clinical characteristics, and outcomes of RSV infection and identify predictors of intensive care unit (ICU) admission. Methods: We conducted a retrospective cohort study of adults aged ≥18 years with laboratory-confirmed RSV infection diagnosed at Hamad Medical Corporation (HMC), Doha, Qatar, between January and December 2023. Demographic, clinical, laboratory, and outcome data were collected. Logistic regression analysis was performed to identify predictors of ICU admission. Results: A total of 211 patients were included, with a median age of 51 years (IQR, 36–68). Comorbidities were present in 135 patients (64.0%), with the most common being diabetes mellitus in 78 patients (37.0%) and chronic kidney disease in 40 patients (19.0%). Hospitalization was required in 111 (52.6%) patients, and 11 (5.2%) were admitted to the ICU. Overall mortality was low, with only 1 (0.47%) patient. Chronic obstructive pulmonary disease (COPD) (OR 18.48, 95% CI 2.32–146.75) and neurologic disease (OR 6.98, 95% CI 1.70–28.69) were independent predictors of ICU admission. RSV activity peaked in November at 77 cases, indicating marked seasonality. Conclusion: RSV infection in adults in Qatar was associated with substantial healthcare utilization but low mortality. Most patients experienced favorable outcomes. COPD and neurologic disease were major predictors of severe illness. These findings support targeted preventive and management strategies in high-risk populations.
- 1 January 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2026 (4)
Open AccessEpidemiological, clinical characteristics and outcomes of RSV infection in adult patients in Qatar
Background: Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of respiratory illness in adults, particularly among older individuals and those with chronic comorbidities. Data on RSV epidemiology and outcomes in the Middle East remain limited, which is particularly important given the high burden of chronic metabolic diseases in the region and its potential implications. Objective: To evaluate the epidemiology, clinical characteristics, and outcomes of RSV infection and identify predictors of intensive care unit (ICU) admission. Methods: We conducted a retrospective cohort study of adults aged ≥18 years with laboratory-confirmed RSV infection diagnosed at Hamad Medical Corporation (HMC), Doha, Qatar, between January and December 2023. Demographic, clinical, laboratory, and outcome data were collected. Logistic regression analysis was performed to identify predictors of ICU admission. Results: A total of 211 patients were included, with a median age of 51 years (IQR, 36–68). Comorbidities were present in 135 patients (64.0%), with the most common being diabetes mellitus in 78 patients (37.0%) and chronic kidney disease in 40 patients (19.0%). Hospitalization was required in 111 (52.6%) patients, and 11 (5.2%) were admitted to the ICU. Overall mortality was low, with only 1 (0.47%) patient. Chronic obstructive pulmonary disease (COPD) (OR 18.48, 95% CI 2.32–146.75) and neurologic disease (OR 6.98, 95% CI 1.70–28.69) were independent predictors of ICU admission. RSV activity peaked in November at 77 cases, indicating marked seasonality. Conclusion: RSV infection in adults in Qatar was associated with substantial healthcare utilization but low mortality. Most patients experienced favorable outcomes. COPD and neurologic disease were major predictors of severe illness. These findings support targeted preventive and management strategies in high-risk populations.
- Open Access
- 1 January 2024
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (4) , 51
Epidemiology, clinical characteristics, and treatment outcomes of leishmaniasis in Qatar: A retrospective study
Background: Leishmaniasis is an emerging tropical infectious disease in Qatar. It is caused by the protozoan parasite of the Leishmania genus, which is endemic in many regions of the world, including the Middle East. In Qatar, there is limited data about this disease, which is hindering the efficient planning and implementation of disease prevention and control measures. Therefore, to address this knowledge gap, we conducted a retrospective study to gather information on the prevalence, clinical characteristics, as well as outcomes of leishmaniasis treatment. The primary objective of this study is to provide a comprehensive analysis of leishmaniasis cases in Qatar over seven years (2016–2022). The findings of this study offer valuable insights that can guide the development of a national registry and treatment program for leishmaniasis in Qatar. Methods: Using a retrospective cross-sectional study design, clinical and epidemiological data of all documented cases of leishmaniasis in Qatar between 2016 and 2022 were collected from electronic medical records at Hamad Medical Corporation (HMC). Results: A total of sixty-eight cases of leishmaniasis were detected in Qatar between 2016 and 2022. Males were predominant (69.12%) with a median age of 33 years. Our study revealed a higher incidence of leishmaniasis among individuals of Syrian nationality, followed by Pakistani and Sudanese, thus promoting further investigation into the underlying factors contributing to this health disparity. Our findings revealed important epidemiological trends, highlighted key clinical characteristics, identified risk factors associated with susceptibility to leishmaniasis, and reported treatment outcomes. Conclusion: This retrospective study presents the first comprehensive analysis of leishmaniasis in Qatar, shedding light on the epidemiology, clinical characteristics, and treatment outcomes of the disease. The data generated from this study can serve as a guide for authorities in establishing a national registry and treatment program for leishmaniasis in Qatar. Implementing these measures will contribute to the effective management and control of leishmaniasis, ultimately improving patient outcomes and public health in the country.
- 1 January 2024
- Published by Hamad bin Khalifa University Press (HBKU Press) in Qatar Medical Journal
- Vol. 2024 (4) , 51
Open AccessEpidemiology, clinical characteristics, and treatment outcomes of leishmaniasis in Qatar: A retrospective study
Background: Leishmaniasis is an emerging tropical infectious disease in Qatar. It is caused by the protozoan parasite of the Leishmania genus, which is endemic in many regions of the world, including the Middle East. In Qatar, there is limited data about this disease, which is hindering the efficient planning and implementation of disease prevention and control measures. Therefore, to address this knowledge gap, we conducted a retrospective study to gather information on the prevalence, clinical characteristics, as well as outcomes of leishmaniasis treatment. The primary objective of this study is to provide a comprehensive analysis of leishmaniasis cases in Qatar over seven years (2016–2022). The findings of this study offer valuable insights that can guide the development of a national registry and treatment program for leishmaniasis in Qatar. Methods: Using a retrospective cross-sectional study design, clinical and epidemiological data of all documented cases of leishmaniasis in Qatar between 2016 and 2022 were collected from electronic medical records at Hamad Medical Corporation (HMC). Results: A total of sixty-eight cases of leishmaniasis were detected in Qatar between 2016 and 2022. Males were predominant (69.12%) with a median age of 33 years. Our study revealed a higher incidence of leishmaniasis among individuals of Syrian nationality, followed by Pakistani and Sudanese, thus promoting further investigation into the underlying factors contributing to this health disparity. Our findings revealed important epidemiological trends, highlighted key clinical characteristics, identified risk factors associated with susceptibility to leishmaniasis, and reported treatment outcomes. Conclusion: This retrospective study presents the first comprehensive analysis of leishmaniasis in Qatar, shedding light on the epidemiology, clinical characteristics, and treatment outcomes of the disease. The data generated from this study can serve as a guide for authorities in establishing a national registry and treatment program for leishmaniasis in Qatar. Implementing these measures will contribute to the effective management and control of leishmaniasis, ultimately improving patient outcomes and public health in the country.
- Open Access
- 11 September 2023
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 16 (11) , 1802-1805
Clinical manifestations and outcome of Mpox infection in Qatar: An observational study during the 2022 outbreak
- 11 September 2023
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 16 (11) , 1802-1805
Open AccessClinical manifestations and outcome of Mpox infection in Qatar: An observational study during the 2022 outbreak
- Open Access
- 30 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (39) , e30618
Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
Introduction: Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing cytokine storm. Methods and analysis: We aim to conduct an open-label randomized controlled trial to evaluate the efficacy and safety of adding colchicine to tocilizumab among patients with severe COVID-19 pneumonia to reduce the rate of invasive mechanical ventilation and mortality. We will include patients with severe COVID-19 pneumonia who received tocilizumab according to our local guidelines. Enrolled patients will be then randomized in 1:1 to colchicine versus no colchicine. Patients will be followed up for 30 days. The primary outcome is the rate of invasive mechanical ventilation and will be determined using Cox proportional hazard model. Discussion: Given colchicine’s ease of use, low cost, good safety profile, and having different anti-inflammatory mechanism of action than other IL-6 blockade, colchicine might serve as a potential anti-inflammatory agent among patients with severe COVID-19 pneumonia. This study will provide valuable insights on the use of colchicine in severe COVID-19 when added to IL-6 antagonists. Ethics and dissemination: The Medical Research Center and Institutional Review Board at Hamad Medical Corporation in Qatar approved the study protocol (MRC-01-21-299). Results of the analysis will be submitted for publication in a peer-reviewed journal.
- 30 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (39) , e30618
Open AccessAdding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
Introduction: Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing cytokine storm. Methods and analysis: We aim to conduct an open-label randomized controlled trial to evaluate the efficacy and safety of adding colchicine to tocilizumab among patients with severe COVID-19 pneumonia to reduce the rate of invasive mechanical ventilation and mortality. We will include patients with severe COVID-19 pneumonia who received tocilizumab according to our local guidelines. Enrolled patients will be then randomized in 1:1 to colchicine versus no colchicine. Patients will be followed up for 30 days. The primary outcome is the rate of invasive mechanical ventilation and will be determined using Cox proportional hazard model. Discussion: Given colchicine’s ease of use, low cost, good safety profile, and having different anti-inflammatory mechanism of action than other IL-6 blockade, colchicine might serve as a potential anti-inflammatory agent among patients with severe COVID-19 pneumonia. This study will provide valuable insights on the use of colchicine in severe COVID-19 when added to IL-6 antagonists. Ethics and dissemination: The Medical Research Center and Institutional Review Board at Hamad Medical Corporation in Qatar approved the study protocol (MRC-01-21-299). Results of the analysis will be submitted for publication in a peer-reviewed journal.
- Open Access
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar
Effectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence. Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91).
Open AccessEffectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar
Effectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence. Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91).
- Open Access
- 17 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23263
Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study
Stenotrophomonas maltophilia is a rapidly emerging nosocomial pathogen with intrinsic or acquired resistance mechanisms to several antibiotic classes. It can cause life-threatening opportunistic pneumonia, particularly among hospitalized patients. Incidence of infections by S. maltophilia has been reported as 0.07-0.4% of hospital discharges, but its mortality is 20 -60%. This is the first study from Qatar indexing the clinical and epidemiological characteristics and antibiotic susceptibility of S. maltophilia. This retrospective descriptive epidemiological study was conducted in 6 tertiary care hospitals under Hamad Medical Corporation in Doha, Qatar, analyzing inpatient respiratory isolates of S. maltophilia during 2016-17. Out-patients, children below 14 years, and non-respiratory samples except blood cultures in patients with pneumonia were excluded. Clinical records were reviewed to identify possible risk factors. Infection and colonization were identified using the Centers for Disease Control and Prevention (CDC) algorithm for clinically defined pneumonia and statistically analyzed using the chi-square test and Pearson's correlation. S. maltophilia was isolated from 2.07% (317/15312) of all respiratory samples received in the microbiology lab during our study period. Three hundred seventeen patients studied had a mean age of 60 ± 20 years, and 68% were men. Most of the isolates were from sputum (179), followed by tracheal aspirate (82) and bronchoscopy (42). Fourteen blood culture samples from patients diagnosed with pneumonia were also included. 67% were hospitalized for more than two weeks, 39.1% were on mechanical ventilators, and 88% had received a broad-spectrum antibiotic before the event. 29.1% were deemed to have an infection and 70.9% colonization. Incidence of infection in those with Charlson’s Co-morbidity Index (CCI) ≥ 3 was 36.5% compared to 24.2% in those with CCI < 3 (Relative Risk (RR)=1.52; 95% CI: 1.04,2.18; p=0.01). Patients with recent chemotherapy, immunosuppressant, or steroid use had a significantly higher infection risk than those without (69.2% v/s 23.3% RR=2.96; 95% CI:2.2,3.9; pS. maltophilia is a frequent nosocomial colonizer, but it can cause nosocomial pneumonia in almost one-third of cases, specifically in immunocompromised and patients with CCI ≥ 3 with a high risk of mortality due to ventilator-associated pneumonia (VAP) in those with IBMP-10 ≥ 2. Prolonged hospital stay is a risk factor for colonization by S. maltophilia, while recent chemotherapy, immunosuppressant, or steroid use are risk factors for hospital-acquired pneumonia due to S. maltophilia. TMP-SMX and levofloxacin are the only reliable agents for monotherapy of respiratory infections due to S. maltophilia in Qatar.
- 17 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23263
Open AccessClinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study
Stenotrophomonas maltophilia is a rapidly emerging nosocomial pathogen with intrinsic or acquired resistance mechanisms to several antibiotic classes. It can cause life-threatening opportunistic pneumonia, particularly among hospitalized patients. Incidence of infections by S. maltophilia has been reported as 0.07-0.4% of hospital discharges, but its mortality is 20 -60%. This is the first study from Qatar indexing the clinical and epidemiological characteristics and antibiotic susceptibility of S. maltophilia. This retrospective descriptive epidemiological study was conducted in 6 tertiary care hospitals under Hamad Medical Corporation in Doha, Qatar, analyzing inpatient respiratory isolates of S. maltophilia during 2016-17. Out-patients, children below 14 years, and non-respiratory samples except blood cultures in patients with pneumonia were excluded. Clinical records were reviewed to identify possible risk factors. Infection and colonization were identified using the Centers for Disease Control and Prevention (CDC) algorithm for clinically defined pneumonia and statistically analyzed using the chi-square test and Pearson's correlation. S. maltophilia was isolated from 2.07% (317/15312) of all respiratory samples received in the microbiology lab during our study period. Three hundred seventeen patients studied had a mean age of 60 ± 20 years, and 68% were men. Most of the isolates were from sputum (179), followed by tracheal aspirate (82) and bronchoscopy (42). Fourteen blood culture samples from patients diagnosed with pneumonia were also included. 67% were hospitalized for more than two weeks, 39.1% were on mechanical ventilators, and 88% had received a broad-spectrum antibiotic before the event. 29.1% were deemed to have an infection and 70.9% colonization. Incidence of infection in those with Charlson’s Co-morbidity Index (CCI) ≥ 3 was 36.5% compared to 24.2% in those with CCI < 3 (Relative Risk (RR)=1.52; 95% CI: 1.04,2.18; p=0.01). Patients with recent chemotherapy, immunosuppressant, or steroid use had a significantly higher infection risk than those without (69.2% v/s 23.3% RR=2.96; 95% CI:2.2,3.9; pS. maltophilia is a frequent nosocomial colonizer, but it can cause nosocomial pneumonia in almost one-third of cases, specifically in immunocompromised and patients with CCI ≥ 3 with a high risk of mortality due to ventilator-associated pneumonia (VAP) in those with IBMP-10 ≥ 2. Prolonged hospital stay is a risk factor for colonization by S. maltophilia, while recent chemotherapy, immunosuppressant, or steroid use are risk factors for hospital-acquired pneumonia due to S. maltophilia. TMP-SMX and levofloxacin are the only reliable agents for monotherapy of respiratory infections due to S. maltophilia in Qatar.
- Open Access
SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity
There is a lack of predictive markers for early and rapid identification of disease progression in COVID-19 patients. Our study aims at identifying microRNAs (miRNAs)/small nucleolar RNAs (snoRNAs) as potential biomarkers of COVID-19 severity. Using differential expression analysis of microarray data (n = 29), we identified hsa-miR-1246, ACA40, hsa-miR-4532, hsa-miR-145-5p, and ACA18 as the top five differentially expressed transcripts in severe versus asymptomatic, and ACA40, hsa-miR-3609, ENSG00000212378 (SNORD78), hsa-miR-1231, hsa-miR-885-3p as the most significant five in severe versus mild cases. Moreover, we found that white blood cell (WBC) count, absolute neutrophil count (ANC), neutrophil (%), lymphocyte (%), red blood cell (RBC) count, hemoglobin, hematocrit, D-Dimer, and albumin are significantly correlated with the identified differentially expressed miRNAs and snoRNAs. We report a unique miRNA and snoRNA profile that is associated with a higher risk of severity in a cohort of SARS-CoV-2 infected patients. Altogether, we present a differential expression analysis of COVID-19-associated microRNA (miRNA)/small nucleolar RNA (snoRNA) signature, highlighting their importance in SARS-CoV-2 infection.
Open AccessSnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity
There is a lack of predictive markers for early and rapid identification of disease progression in COVID-19 patients. Our study aims at identifying microRNAs (miRNAs)/small nucleolar RNAs (snoRNAs) as potential biomarkers of COVID-19 severity. Using differential expression analysis of microarray data (n = 29), we identified hsa-miR-1246, ACA40, hsa-miR-4532, hsa-miR-145-5p, and ACA18 as the top five differentially expressed transcripts in severe versus asymptomatic, and ACA40, hsa-miR-3609, ENSG00000212378 (SNORD78), hsa-miR-1231, hsa-miR-885-3p as the most significant five in severe versus mild cases. Moreover, we found that white blood cell (WBC) count, absolute neutrophil count (ANC), neutrophil (%), lymphocyte (%), red blood cell (RBC) count, hemoglobin, hematocrit, D-Dimer, and albumin are significantly correlated with the identified differentially expressed miRNAs and snoRNAs. We report a unique miRNA and snoRNA profile that is associated with a higher risk of severity in a cohort of SARS-CoV-2 infected patients. Altogether, we present a differential expression analysis of COVID-19-associated microRNA (miRNA)/small nucleolar RNA (snoRNA) signature, highlighting their importance in SARS-CoV-2 infection.
- Open Access
- 1 July 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 108, 116-118
The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
- 1 July 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 108, 116-118
Open AccessThe initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
- Open Access
- 7 April 2021
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 104 (4) , 1472-1475
Case Report: Prolonged Viral Shedding in Six COVID-19 Patients
COVID-19 has surfaced as a multi-organ disease predominantly affecting the respiratory system. Detection of the viral RNA through reverse transcriptase–PCR (RT-PCR) from a nasopharyngeal or throat sample is the preferred method of diagnosis. Recent evidence has suggested that COVID-19 patients can shed the SARS-CoV-2 for several weeks. Herein, we report six cases of COVID-19 who had persistently positive SARS-CoV-2 on repeat RT-PCR testing reaching up to 9 weeks. The spectrum of cases described ranges from asymptomatic infection to severe COVID-19 pneumonia. A full understanding of the virus’s transmission dynamics needs further research. Prolonged viral shedding currently has unclear implications on the management and isolation decisions—the role of the cycle threshold (Ct) value in guiding therapeutic decisions is yet to be clarified. More data on the relationship between Ct values and viral cultivation are needed, especially in patients with prolonged viral shedding, to understand the virus’s viability and infectivity.
- 7 April 2021
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 104 (4) , 1472-1475
Open AccessCase Report: Prolonged Viral Shedding in Six COVID-19 Patients
COVID-19 has surfaced as a multi-organ disease predominantly affecting the respiratory system. Detection of the viral RNA through reverse transcriptase–PCR (RT-PCR) from a nasopharyngeal or throat sample is the preferred method of diagnosis. Recent evidence has suggested that COVID-19 patients can shed the SARS-CoV-2 for several weeks. Herein, we report six cases of COVID-19 who had persistently positive SARS-CoV-2 on repeat RT-PCR testing reaching up to 9 weeks. The spectrum of cases described ranges from asymptomatic infection to severe COVID-19 pneumonia. A full understanding of the virus’s transmission dynamics needs further research. Prolonged viral shedding currently has unclear implications on the management and isolation decisions—the role of the cycle threshold (Ct) value in guiding therapeutic decisions is yet to be clarified. More data on the relationship between Ct values and viral cultivation are needed, especially in patients with prolonged viral shedding, to understand the virus’s viability and infectivity.